NEW YORK, May 28, 2012 /PRNewswire-iReach/ -- Clinilabs, an early phase and specialty CRO that provides clinical drug development services to the pharmaceutical industry, today announced that they have opened a second Phase I unit in Southern New Jersey. The 50-bed capacity, 15,000 square foot Specialty Pharma Phase I Unit features semi private rooms, a large PK sampling facility, a bioanalytic laboratory, pharmacy, and exam rooms.
Since 2001, Clinilabs has successfully completed clinical trials involving healthy, adult human volunteers and specialty patient populations. The staff has accrued experience in over 800 clinical studies, offering clients the service capacity of a big CRO – delivered by an organization that is right-sized and priced for early phase projects. The opening of the New Jersey Specialty Pharma Phase I Unit expands services currently offered at the company's 50 bed, state-of-the-art, Phase I unit in Manhattan, raising total bed capacity to 100.
"I am pleased to announce the opening of our new unit in Eatontown, New Jersey", states Dr. Gary Zammit. "This unit allows us to expand our Phase I capacity in two locations, providing first-in-human through end-of-phase II CRO services to our clients. We are now able to enroll larger samples of normal healthy volunteers and patient populations at our two units and at investigator sites worldwide."
About Clinilabs Inc.
Clinilabs is a contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies – services that can be scaled as needed to meet the requirements of any clinical development program. For more information, please visit www.clinilabs.com.
Media Contact: Hannah DAoust Clinilabs, 646-215-6480, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
Copyright©2010 PR Newswire.
All rights reserved